Revvity Reports Q1 Earnings Beat with Organic Growth and Divestiture Plans
Revvity reported first-quarter results that exceeded internal expectations, posting a 3% organic growth rate and an adjusted operating margin of 23.6%. The company also announced plans to divest its China immunodiagnostics unit, which is expected to improve future growth metrics but reduce EPS by approximately $0.15.
Tickers: $RVTY
Topics: divestiture_announcement financial_performance guidance_update